Olmesartan medoxomil is an angiotensin II receptor antagonist used to reduce and control hypertension (high blood pressure). Generic Olmesartan medoxomil is available outside of the US as olmesartan medoxomil. Common side effects of Olmesartan medoxomil include dizziness, bronchitis, back pain, headache, flu-like symptoms, hematuria, and sinusitis.

Olmesartan medoxomil(CAS NO:144689-63-4) is available in strengths of 5, 20, or 40 mg of olmesartan medoxomil tablets. The usual recommended starting dose is 20 mg per day but dosage in pediatric patients needs to be calculated for each individual. Potentially serious side effects include difficulty with breathing or swallowing, chest pain, cough, vertigo, abdominal pain, hyperkalemia, renal failure, and rhabdomyolysis.

Olmesartan medoxomil should not be used in pregnancy due to possible fetal damage or death; lactating women and their doctors need to weigh the advantages vs the possible harm if the drug is used. There is only one study in pediatric patients (ages 1-16 years) that suggests that this compound is well tolerated with similar side effects seen in adults.

As a widely used medicine,Olmesartan medoxomil(CAS NO:144689-63-4) also has some side effects.

The incidence of adverse effects with Olmesartan medoxomil is reported as similar to placebo; the only adverse effect that occurred in >1% of patients treated with it and more frequently than placebo was dizziness (3% vs 1%). The full prescribing information for Olmesartan medoxomil notes as with all drugs that act directly on the renin-angiotensin system, olmesartan is contraindicated in pregnancy and can cause injury and even death to the developing fetus.

In studies of angiotensin II receptor antagonists such as olmesartan, patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen have been reported. There has been no long-term use of this medicine in patients with unilateral or bilateral renal artery stenosis, but similar results may be expected. Olmesartan, a drug prescribed to control blood pressure, can cause severe gastrointestinal issues, say Mayo Clinic researchers. The symptoms, which include nausea, vomiting, diarrhea, weight loss, and electrolyte abnormalities, are common among those who have celiac disease.

Mayo Clinic physicians treated 22 patients with life threatening gastrointestinal (gastritis, enteritis) symptoms similar to celiac disease, including intestinal inflammation and abnormalities from 2008 to 2011. Patients came from 17 states, and some had been diagnosed with celiac disease. They had chronic diarrhea and weight loss; the median weight loss was 39 pounds, and one patient lost 125 pounds. Fourteen of the 22 were hospitalized because of the severity of their symptoms. When given a blood test, however, these patients didn't come back with results typical of celiac disease. They also didn't respond to treatments such as gluten-free diets.

After examining their medications, Mayo Clinic gastroenterologist Joseph Murray, M.D., pulled several of the patients off Olmesartan. Their symptoms dramatically improved. Eventually, all 22 were taken off the drug, and all showed improvement. Eighteen of the 22 patients had intestinal biopsies after stopping the medication and showed improvement.

"We thought these cases were celiac disease initially because their biopsies showed features very like celiac disease, such as inflammation," says Dr. Murray, the lead author. "What made them different was they didn't have the antibodies in their blood that are typical for celiac disease."

Olmesartan--prescribed for the treatment of hypertension, or high blood pressure --works by blocking substances that tighten blood vessels, allowing blood to flow more smoothly and the heart to pump more efficiently, according to the U.S. National Library on Medicine. "It's really an awareness issue. We want doctors to be aware of this issue, so if they see a patient who is having this type of syndrome--they think about medications as a possible association," Dr. Murray says. "We've reported an association. What needs to be known next is the science to understand why there is such an association."

Want to learn more information about Olmesartan medoxomil [http://www.guidechem.com/cas-144/144689-63-4.html], you can access the guidechem.com.